The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

Peter Humphrey, a former journalist and private investigator, believes a Chinese surveillance team were monitoring his group ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...